Rallybio Corporation

NASDAQ:RLYB

Biotechnology

Healthcare
$15.26 +0.03%

+$0.01 today

Market cap
$82.16M
Beta
-0.88
P/E (TTM)
-11.6
EPS (TTM)
-$1.37
52W Low $2.40High $17.57

Volume 0.03M

Average 0.25M

RLYB Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Rallybio CorporationNASDAQ: RLYB

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables grows, but more slowly than its trailing trend

Q1 FY2026 accounts payables of $814K rose 567.2% year over year, behind the +871.4% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables amounted to 17.7% of revenue in FY2025, down 92.0 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +567.2% toward the trailing-twelve-month pace of +871.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$814K+669.2% QoQ
Last fiscal yearDec 2025
-$152K-78.2% YoY
LTMMar 2026
$540K+871.4% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+567.2%——
1 year-78.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(152K) USD
Year-over-year change
+78.2%

Accounts Payables vs competitors

How RLYB compares with its peers on the latest reported figures

  • RLYB's LTM Mar 2026 accounts payables of $540K is the smallest of the 4 companies compared; the peer median is $646K.
  • Its year-over-year change of +871.4% is the highest of 4, against a peer median of +21.4%.
  • Accounts payables amounts to 62.9% of revenue for RLYB, versus a peer median of 1113.4%.
RLYB Competitors Peer median
Accounts Payables for RLYB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IBIOiBio, Inc.LTM Jun 2026$2.22M +21.4%—2223.0%
QTTBQ32 Bio Inc.LTM Mar 2026$2.06M -8.4%+19.4%3.8%
BOLDBoundless Bio, Inc.LTM Mar 2026$646K +158.8%-5.1%—
RLYBRallybio CorporationLTM Mar 2026$540K +871.4%—62.9%
Peer median (excluding RLYB) $646K+21.4%+7.1%1113.4%

Competitors are the stored peer set for RLYB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(47.01M)(66.65M)(74.56M)(57.78M)(8.98M)
Depreciation & Amortization109K167K150K131K92K
Deferred Income Tax00000
Stock-Based Compensation3.65M9.5M10.92M7.99M5.31M
Change in Working Capital(3.78M)(936K)4.28M(258K)(4.19M)
Accounts Receivables00000
Inventory00000
Accounts Payables(976K)487K(99K)(698K)(152K)
Other Working Capital(2.8M)(1.42M)4.38M440K(4.04M)
Other Non-Cash Items1.51M640K(1.05M)627K(22.05M)
Operating Cash Flow(45.53M)(57.28M)(60.27M)(49.28M)(29.81M)
Capital Expenditures(333K)(54K)(12K)00
Acquisitions (Net)(2M)(300K)(2.25M)(2M)0
Purchases of Investments(2M)(201.32M)(110.66M)(48.93M)(17.7M)
Sales of Investments2M89.5M138.33M84.43M46.47M
Other Investing Activities(2K)02.25M018.5M
Investing Cash Flow(2.33M)(112.17M)27.66M33.49M47.27M
Debt Repayment00000
Common Stock Issued86.2M51.53M143K5.41M16K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(3.23M)(455K)0(206K)0
Financing Cash Flow82.97M51.08M143K5.2M16K
Effect of Forex Changes00000
Net Change in Cash35.1M(118.38M)(32.46M)(10.59M)17.47M
Free Cash Flow(45.87M)(57.34M)(60.28M)(49.28M)(29.81M)

Rallybio Corporation

NASDAQ:RLYB

Intrinsic Alpha fair value

Locked

Current Price

$15.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.